Mylan (NASDAQ:MYL)‘s stock had its “outperform” rating reissued by equities researchers at Leerink Swann in a note issued to investors on Monday.
A number of other brokerages have also issued reports on MYL. Mizuho boosted their target price on shares of Mylan from $47.00 to $53.00 and gave the company a “buy” rating in a research note on Monday, March 13th. Vetr lowered shares of Mylan from a “strong-buy” rating to a “buy” rating and set a $44.68 target price for the company. in a research note on Monday, February 6th. BTIG Research reissued a “buy” rating and set a $55.00 target price on shares of Mylan in a research note on Tuesday, November 29th. Royal Bank of Canada set a $48.00 target price on shares of Mylan and gave the company a “hold” rating in a research note on Thursday, March 2nd. Finally, Barclays PLC reissued an “equal weight” rating and set a $47.00 target price (up from $44.00) on shares of Mylan in a research note on Saturday, March 11th. One research analyst has rated the stock with a sell rating, nine have given a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the stock. Mylan presently has an average rating of “Buy” and a consensus price target of $52.73.
Mylan (NASDAQ:MYL) traded up 0.33% during mid-day trading on Monday, reaching $42.17. 4,884,893 shares of the company’s stock were exchanged. The firm has a market capitalization of $22.58 billion, a P/E ratio of 45.84 and a beta of 1.14. Mylan has a one year low of $33.60 and a one year high of $50.40. The company’s 50-day moving average is $41.46 and its 200 day moving average is $38.93.
Mylan (NASDAQ:MYL) last posted its quarterly earnings data on Wednesday, March 1st. The company reported $1.57 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.42 by $0.15. Mylan had a net margin of 2.50% and a return on equity of 22.04%. During the same quarter in the previous year, the business earned $1.22 EPS. Equities analysts predict that Mylan will post $5.33 earnings per share for the current fiscal year.
Your IP Address:
Institutional investors have recently made changes to their positions in the company. State Street Corp increased its position in shares of Mylan by 7.8% in the fourth quarter. State Street Corp now owns 19,942,043 shares of the company’s stock worth $760,788,000 after buying an additional 1,446,244 shares in the last quarter. BlackRock Fund Advisors increased its position in shares of Mylan by 9.6% in the third quarter. BlackRock Fund Advisors now owns 13,279,223 shares of the company’s stock worth $506,204,000 after buying an additional 1,166,359 shares in the last quarter. Northern Trust Corp increased its position in shares of Mylan by 2.2% in the third quarter. Northern Trust Corp now owns 5,304,333 shares of the company’s stock worth $202,201,000 after buying an additional 114,280 shares in the last quarter. Norges Bank purchased a new position in shares of Mylan during the fourth quarter worth approximately $166,189,000. Finally, Camber Capital Management LLC increased its position in shares of Mylan by 7.0% in the fourth quarter. Camber Capital Management LLC now owns 4,145,889 shares of the company’s stock worth $158,166,000 after buying an additional 272,889 shares in the last quarter. Institutional investors and hedge funds own 60.89% of the company’s stock.
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
This story was originally published by WKRB News (http://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://www.wkrb13.com/markets/2024156/mylans-myl-outperform-rating-reiterated-at-leerink-swann.html
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.